|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$14.84 0.00 (0.00%) as of 4:30 Tue 10/28
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
161,930,000 |
| Market
Cap: |
2.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.83 - $14.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 733 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,744,285 |
7,104,285 |
| Total Buy Value |
$0 |
$0 |
$50,219,294 |
$71,025,294 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
5 |
7 |
| Total Shares Sold |
0 |
10,461 |
36,753 |
171,903 |
| Total Sell Value |
$0 |
$115,280 |
$277,638 |
$1,687,959 |
| Total People Sold |
0 |
1 |
1 |
2 |
| Total Sell Transactions |
0 |
1 |
3 |
7 |
| End Date |
2025-08-31 |
2025-05-30 |
2024-11-29 |
2023-11-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Rajeev M. |
Director |
– • • |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(19,889,683) |
0 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,694) |
0 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(351,684) |
0 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
351,684 |
|
- |
|
| Martins Ryan |
Chief Financial Officer |
• – – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(374,295) |
0 |
|
- |
|
| Martins Ryan |
Chief Financial Officer |
• – – |
2025-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
374,295 |
|
- |
|
| Palekar Rohan |
Chief Executive Officer |
• • – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(934,273) |
0 |
|
- |
|
| Palekar Rohan |
Chief Executive Officer |
• • – |
2025-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
934,273 |
|
- |
|
| Sarena Francis Willard |
Chief Operating Officer |
• – – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(75,310) |
0 |
|
- |
|
| Mcwherter Charles |
|
– • – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,000) |
0 |
|
- |
|
| Mansbach Harry H |
Chief Medical Officer |
• – – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(352,656) |
0 |
|
- |
|
| Mansbach Harry H |
Chief Medical Officer |
• – – |
2025-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
352,656 |
|
- |
|
| Hayden Michael R |
|
– • – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(165,516) |
0 |
|
- |
|
| Hayden Michael R |
|
– • – |
2025-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(80,904) |
0 |
|
- |
|
| Martins Ryan |
Chief Financial Officer |
• – – |
2025-10-22 |
4 |
OE |
$3.11 |
$256,469 |
D/D |
80,799 |
339,295 |
|
- |
|
| Sarena Francis Willard |
Chief Operating Officer |
• – – |
2025-08-05 |
4 |
D |
$9.69 |
$28,867 |
D/D |
(2,979) |
74,231 |
|
- |
|
| Mansbach Harry H |
Chief Medical Officer |
• – – |
2025-08-01 |
4 |
D |
$9.16 |
$70,349 |
D/D |
(7,680) |
302,656 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-08-01 |
4 |
D |
$9.16 |
$4,782 |
I/I |
(522) |
13,694 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-08-01 |
4 |
D |
$9.16 |
$70,349 |
D/D |
(7,680) |
301,684 |
|
- |
|
| Sarena Francis Willard |
Chief Operating Officer |
• – – |
2025-08-01 |
4 |
D |
$9.16 |
$29,367 |
D/D |
(3,206) |
77,210 |
|
- |
|
| Martins Ryan |
Chief Financial Officer |
• – – |
2025-08-01 |
4 |
D |
$9.16 |
$70,349 |
D/D |
(7,680) |
253,496 |
|
- |
|
| Palekar Rohan |
Chief Executive Officer |
• • – |
2025-08-01 |
4 |
D |
$9.16 |
$511,458 |
D/D |
(55,836) |
808,070 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-07-15 |
4 |
AS |
$11.02 |
$115,280 |
D/D |
(10,461) |
309,364 |
|
41% |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-06-12 |
4 |
D |
$9.62 |
$5,137 |
I/I |
(534) |
14,216 |
|
- |
|
| Le-Nguyen Quoc |
See Remarks |
• – – |
2025-06-12 |
4 |
D |
$9.62 |
$81,751 |
D/D |
(8,498) |
319,825 |
|
- |
|
255 Records found
|
|
Page 1 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
